These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 28730499)

  • 1. Target Inhibition Maps Based on Responses to Kinase Inhibitors.
    Berlow N; Pal R
    Methods Mol Biol; 2017; 1636():507-522. PubMed ID: 28730499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs.
    Pal R; Berlow N
    Pac Symp Biocomput; 2012; ():351-62. PubMed ID: 22174290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
    Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
    Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DeSigN: connecting gene expression with therapeutics for drug repurposing and development.
    Lee BK; Tiong KH; Chang JK; Liew CS; Abdul Rahman ZA; Tan AC; Khang TF; Cheong SC
    BMC Genomics; 2017 Jan; 18(Suppl 1):934. PubMed ID: 28198666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. INTEGRATING GENETIC AND STRUCTURAL DATA ON HUMAN PROTEIN KINOME IN NETWORK-BASED MODELING OF KINASE SENSITIVITIES AND RESISTANCE TO TARGETED AND PERSONALIZED ANTICANCER DRUGS.
    Verkhivker GM
    Pac Symp Biocomput; 2016; 21():45-56. PubMed ID: 26776172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines.
    Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles.
    Li X; Xu Y; Cui H; Huang T; Wang D; Lian B; Li W; Qin G; Chen L; Xie L
    Artif Intell Med; 2017 Nov; 83():35-43. PubMed ID: 28583437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systems Biology Modeling to Study Pathogen-Host Interactions.
    Cesur MF; Durmuş S
    Methods Mol Biol; 2018; 1734():97-112. PubMed ID: 29288450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Integrated Approach to Anti-Cancer Drug Sensitivity Prediction.
    Berlow N; Haider S; Wan Q; Geltzeiler M; Davis LE; Keller C; Pal R
    IEEE/ACM Trans Comput Biol Bioinform; 2014; 11(6):995-1008. PubMed ID: 26357038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of kinase inhibitor response using activity profiling, in vitro screening, and elastic net regression.
    Tran TP; Ong E; Hodges AP; Paternostro G; Piermarocchi C
    BMC Syst Biol; 2014 Jun; 8():74. PubMed ID: 24961498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors.
    Cichonska A; Ravikumar B; Parri E; Timonen S; Pahikkala T; Airola A; Wennerberg K; Rousu J; Aittokallio T
    PLoS Comput Biol; 2017 Aug; 13(8):e1005678. PubMed ID: 28787438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trop-2 Induces Tumor Growth Through AKT and Determines Sensitivity to AKT Inhibitors.
    Guerra E; Trerotola M; Tripaldi R; Aloisi AL; Simeone P; Sacchetti A; Relli V; D'Amore A; La Sorda R; Lattanzio R; Piantelli M; Alberti S
    Clin Cancer Res; 2016 Aug; 22(16):4197-205. PubMed ID: 27022065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
    Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
    Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling of signaling crosstalk-mediated drug resistance and its implications on drug combination.
    Sun X; Bao J; You Z; Chen X; Cui J
    Oncotarget; 2016 Sep; 7(39):63995-64006. PubMed ID: 27590512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer.
    Jaiswal A; Yadav B; Wennerberg K; Aittokallio T
    Methods Mol Biol; 2019; 1888():205-217. PubMed ID: 30519949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein-Peptide Interaction Design: PepCrawler and PinaColada.
    Zaidman D; Wolfson HJ
    Methods Mol Biol; 2017; 1561():279-290. PubMed ID: 28236244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics.
    Giansanti P; Preisinger C; Huber KV; Gridling M; Superti-Furga G; Bennett KL; Heck AJ
    ACS Chem Biol; 2014 Jul; 9(7):1490-8. PubMed ID: 24804581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.